TGFB1 and neoplasm: To further determine the mechanism of action, single-cell transcriptomic analysis from CD45+ immune-infiltrating cells collected from tumors on day 12 after 2 doses of agents and prior to tumor cures (Figure 6C) was used to compare the NC410 combination groups with anti–PD-L1 or the TGF-β trap control devoid of PD-L1 binding.